OWENS & MINOR INC/VA/ SEC 10-Q Report

Owens & Minor Inc., a leading healthcare logistics company, has released its Form 10-Q report for the second quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational activities, highlighting both achievements and challenges faced during the period.

Financial Highlights

• Net Revenue: $681.9 million, reflecting a slight increase from $660.4 million in the same period last year, indicating stable sales performance.
• Gross Profit: $324.6 million, calculated as Net Revenue minus Cost of Net Revenue, showing a decrease from the previous year due to increased operating costs.
• Operating (Loss) Income: $(39.7) million, compared to an income of $16.9 million last year, primarily due to higher operating expenses and a significant transaction breakage fee.
• Net Loss: $(869.1) million, significantly impacted by a large loss from discontinued operations, compared to a loss of $31.9 million in the previous year.
• Basic Loss Per Common Share: $(11.30), compared to $(0.42) in the previous year, reflecting the substantial net loss incurred during the period.

Business Highlights

• Revenue Segments: The company reported revenue from various product lines, including Diabetes ($191 million for Q2 2025), Sleep Therapy ($182 million for Q2 2025), Home Respiratory Therapy ($110 million for Q2 2025), Ostomy ($52 million for Q2 2025), Wound Care ($47 million for Q2 2025), and Urology ($29 million for Q2 2025). The 'Other' category contributed $72 million for Q2 2025.
• Customer Segments: Revenue was also broken down by payor type, with Commercial Payors contributing $551 million for Q2 2025, Medicare $122 million, and Medicaid $9 million.
• Discontinued Operations: The company is in the final stages of divesting its Products & Healthcare Services (P&HS) segment, which has been classified as discontinued operations. This segment reported net revenue of $1.98 billion for Q2 2025.
• Operational Challenges: The company faced significant operational challenges, including a $106 million goodwill impairment charge and a $649 million loss on classification to held for sale for the P&HS segment.
• Exit and Realignment: The company incurred $2.5 million in exit and realignment charges for Q2 2025, related to strategic operational improvements and the wind-down of the Fusion5 business.
• Future Outlook: The company is actively engaged in discussions for the sale of its P&HS segment and expects the divestiture to be completed within one year. This is part of a broader strategy to optimize operations and focus on core business activities.

SEC Filing: OWENS & MINOR INC/VA/ [ OMI ] - 10-Q - Aug. 11, 2025